Robert Blum, Cytokinetics CEO
May 13, 2024 09:33 AM EDT
R&D
Pharma

Cy­to­ki­net­ics lifts cur­tain on Phase 3 afi­camten da­ta, com­mer­cial launch prep un­der­way

Ayisha Sharma

News Reporter

Cy­to­ki­net­ics de­tailed re­sults on Mon­day from a late-stage tri­al of afi­camten for a rare heart dis­ease, and the com­pa­ny is al­ready hir­ing med­ical af­fairs and …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

Califf, on his way out at FDA, pre­dicts agency tug-of-war be­tween Ra­maswamy and RFK Jr.

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

A service from the Financial Times